Abstract.
The survival time of myeloma patients improved from a few months to many years after treatment with melphalan. Perhaps chemotherapy more intensive than melphalan-prednisolone should be administered to patients at risk of early death. Therefore, early death must be accurately predicted. We analyzed 93 patients with recently diagnosed myeloma and found that 13 (14%) died within 6 months (early death). The most common cause of death was bacterial and fungal pneumonia when myeloma became uncontrollable. The response to conventional chemotherapy was poorer in patients at high risk of early death than the control group. Multivariate analysis showed that the serum level of beta-2 microglobulin was the only value that predicted early death.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Murakami, .H., Hayashi, .K., Hatsumi, .N. et al. Risk factors for early death in patients undergoing treatment for multiple myeloma. Ann Hematol 80, 452–455 (2001). https://doi.org/10.1007/s002770100330
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002770100330